Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
SB242235
CHF 0.00
In stock
SYN-1076-M0011 mgCHF 270.00
SYN-1076-M0055 mgCHF 546.00
SYN-1076-M01010 mgCHF 858.00
SYN-1076-M05050 mgINQ
SYN-1076-M100100 mgINQ
Product Details | |
---|---|
Synonyms | SB-242235 |
Product Type | Chemical |
Properties | |
Formula | C19H20FN5O |
MW | 353.4 |
CAS | 193746-75-7 |
Purity Chemicals | ≥95% |
Appearance | Solid. |
Solubility | Soluble in DMSO. |
Declaration | Manufactured by SynKinase. |
Other Product Data |
Target: p38 | Kinase Group: CMGC | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
InChi Key | PDTYLGXVBIWRIM-UHFFFAOYSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS | Download PDF |
Product Specification Sheet | |
Datasheet | Download PDF |
Description
The p38 mitogen-activated protein kinase (MAPK) signaling pathway is activated by numerous inflammatory mediators and environmental stresses. SB-242235 is a potent and moderately selective p38 MAP kinase inhibitor that may be an effective therapy for cytokine-mediated diseases such as autoimmune or inflammatory diseases. SB-242235 exhibits good oral availability in preclinical studies and has micromolar or submicomolar in vivo IC(50) values. However it is clear from studies examining SB-242235 effects on metabolism, for instance in chondrocytes and human cartilage that SB-242235 effects can be pleiotropic between species and that care must be taken when studying the interactions of multi-target inhibitors such as SB-242235.
Product References
- Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis: A.M. Badger, et al.; Arthritis Rheum. 43, 175 (2000)
- Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity: J.L. Adams, et al.; Bioorg. Med. Chem. Lett. 11, 2867 (2001)
- SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: preclinical pharmacokinetics: K.W. Ward, et al.; Xenobiotica 32, 221 (2002)